Home
GOVX
GOVX News

Latest GeoVax Labs Inc. (GOVX) News on October 16, 2025

GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions

NewMediaWire

3 days ago

GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions

GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025

NewMediaWire

7 days ago

GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025

GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications

NewMediaWire

22 days ago

GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

GlobeNewswire

22 days ago

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations

NewMediaWire

24 days ago

GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations

GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference

NewMediaWire

a month ago

GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference

GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand

NewMediaWire

3 months ago

GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

NewMediaWire

4 months ago

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

NewMediaWire

4 months ago

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

NewMediaWire

4 months ago

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

NewMediaWire

4 months ago

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

GeoVax to Participate in BIO International Convention 2025

NewMediaWire

4 months ago

GeoVax to Participate in BIO International Convention 2025

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

NewMediaWire

4 months ago

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

NewMediaWire

4 months ago

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

NewMediaWire

4 months ago

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

NewMediaWire

4 months ago

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

NewMediaWire

5 months ago

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

NewMediaWire

5 months ago

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

NewMediaWire

5 months ago

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations

NewMediaWire

5 months ago

GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations

GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025

NewMediaWire

5 months ago

GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025

GeoVax Expands Gedeptin(R) Patent Portfolio

NewMediaWire

5 months ago

GeoVax Expands Gedeptin(R) Patent Portfolio

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

NewMediaWire

5 months ago

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

NewMediaWire

5 months ago

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

NewMediaWire

6 months ago

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

NewMediaWire

6 months ago

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

NewMediaWire

6 months ago

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

NewMediaWire

6 months ago

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

NewMediaWire

6 months ago

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

NewMediaWire

6 months ago

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

TipRanks

6 months ago

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

NewMediaWire

6 months ago

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

MT Newswires

6 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

6 months ago

Top Midday Decliners

GeoVax to Present at the Emerging Growth Conference on April 16, 2025

NewMediaWire

6 months ago

GeoVax to Present at the Emerging Growth Conference on April 16, 2025

MT Newswires

6 months ago

GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall

GeoVax to Present Clinical Data at Upcoming April Industry Events

NewMediaWire

6 months ago

GeoVax to Present Clinical Data at Upcoming April Industry Events

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

NewMediaWire

6 months ago

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com

7 months ago

Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

NewMediaWire

7 months ago

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

GlobeNewswire

7 months ago

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NewMediaWire

7 months ago

GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

NewMediaWire

7 months ago

GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

NewMediaWire

7 months ago

GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

GeoVax to Present at the 37th Annual Roth Conference

NewMediaWire

7 months ago

GeoVax to Present at the 37th Annual Roth Conference

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

NewMediaWire

7 months ago

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

NewMediaWire

7 months ago

GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

NewMediaWire

8 months ago

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

NewMediaWire

8 months ago

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification

NewMediaWire

8 months ago

Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

GlobeNewswire

8 months ago

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health

NewMediaWire

8 months ago

GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health

GeoVax to Present at the Emerging Growth Conference on February 19, 2025

NewMediaWire

8 months ago

GeoVax to Present at the Emerging Growth Conference on February 19, 2025

GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award

NewMediaWire

8 months ago

GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

NewMediaWire

8 months ago

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

NewMediaWire

8 months ago

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative

NewMediaWire

8 months ago

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

NewMediaWire

9 months ago

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide

NewMediaWire

9 months ago

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

NewMediaWire

9 months ago

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

GlobeNewswire

9 months ago

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

NewMediaWire

9 months ago

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

NewMediaWire

9 months ago

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

NewMediaWire

9 months ago

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GlobeNewswire

10 months ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GlobeNewswire

a year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GlobeNewswire

a year ago

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

GuruFocus.com

a year ago

Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax Labs initiated with a Buy at Alliance Global Partners

TipRanks

a year ago

GeoVax Labs initiated with a Buy at Alliance Global Partners

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GlobeNewswire

a year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com

a year ago

Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire

a year ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

GeoVax Labs, Inc. (GOVX): A Hot Penny Stock On The Move

Insider Monkey

a year ago

GeoVax Labs, Inc. (GOVX): A Hot Penny Stock On The Move

GeoVax to Participate in Upcoming Investor Conferences in September

GlobeNewswire

a year ago

GeoVax to Participate in Upcoming Investor Conferences in September

MT Newswires

a year ago

GeoVax Labs Enters Deal to Raise $5 Million in Equity Offering

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GlobeNewswire

a year ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?

Zacks

a year ago

Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

GlobeNewswire

a year ago

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

MT Newswires

a year ago

GeoVax Labs Raises $8.5 Million Through in Direct Offering of 1.7 Million Shares

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

GlobeNewswire

a year ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

WHO declares mpox a public health emergency as variant emerges

Yahoo Finance Video

a year ago

WHO declares mpox a public health emergency as variant emerges

Mpox Worries Have Sent This Microcap Stock Sky High

Barrons.com

a year ago

Mpox Worries Have Sent This Microcap Stock Sky High

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

GlobeNewswire

a year ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GlobeNewswire

a year ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GlobeNewswire

a year ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GlobeNewswire

a year ago

GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024

GlobeNewswire

a year ago

GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

GeoVax to Present at the Emerging Growth Conference on July 18, 2024

NewMediaWire

a year ago

GeoVax to Present at the Emerging Growth Conference on July 18, 2024

MT Newswires

a year ago

Top Premarket Gainers

GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market

NewMediaWire

a year ago

GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market

GeoVax Provides First Half 2024 Business Update

NewMediaWire

a year ago

GeoVax Provides First Half 2024 Business Update

GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA

NewMediaWire

a year ago

GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA

GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1

NewMediaWire

a year ago

GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1

MT Newswires

a year ago

Top Premarket Decliners

GeoVax to Present at BIO International Convention 2024

NewMediaWire

a year ago

GeoVax to Present at BIO International Convention 2024

Share on Social Networks: